Novartis firstly launch a new bone Paget's disease therapy.

Novartis Korea has launched the sale of Aclastar (zoledronic acid 5mg injection) for a new treatment of Paget's disease, a class of the biphosphonates, which suppresses re-uptake of destroyed bone cells by administering it via vein slowly for 15 minutes a dose unlike the conventional oral therapy.

The clinical study published in New England Journal of Medicine in 2005 reported that the effic...